ASSESSMENT OF SAFETY OF LYOPHILIZED SUBSTANCE OF ANTIBACTERIAL PEPTIDE COMPLEX


Cite item

Full Text

Abstract

Aim. To assessment acute and chronic toxicity and local irritative effect of antibacterial peptide complex (ABC) substance extracted from interferon preparations. Materials and methods. Preclinical assessment of ABC substance was performed according to «Requirements for preclinical study of overall toxicity of new pharmacological substances». Results. Series of experiments showed that single or prolonged (during 30 days) administration of ABC substance solution to mice intragastrically or rectally in maximal doses did not lead to death of experimental animals or pathological changes in their organs during pathomorphological and histological studies. Assessment of immune system state showed that administration of solution of studied substance during 1 month in dose 25 times higher than therapeutic leaded to stimulation of phagocytic activity of peripheral blood neutrophils. Conclusion. Assessment of acute and chronic toxicity showed that substance of ABC synthesized by virus-induced donor leukocytes during interferon synthesis is well tolerated by experimental animals, does not render toxic effects on their organisms, and possesses immunomodulating activity.

About the authors

L. V Volkova

Branch of Scientific-Manufacturing Organization «Microgen» — Scientific-Manufacturing Organization «Biomed», Perm, Russia

A. V Kazyanin

Branch of Scientific-Manufacturing Organization «Microgen» — Scientific-Manufacturing Organization «Biomed», Perm, Russia

T. A Tyureva

Branch of Scientific-Manufacturing Organization «Microgen» — Scientific-Manufacturing Organization «Biomed», Perm, Russia

S. A Pestereva

Branch of Scientific-Manufacturing Organization «Microgen» — Scientific-Manufacturing Organization «Biomed», Perm, Russia

References

  1. Волкова Л.В., Коробов В.П. Антибактериальный препарат. Патент 2003105421, 2003.
  2. Волкова Л.В. Косарева П.В.Попов В.Ф. Тимашева О.А. Антибактериальная активность пептидного комплекса, выделенного из препаратов лейкоцитарного интерферона. Журн. микробиол. 2005, 5: 54—57.
  3. Государственные испытания и регистрация новых медицинских иммунобиологических препаратов. СП 3.3.2.561-96.
  4. Измеров Н.Ф., Саноцкий И.В., Сидоров К.К. Параметры токсикометрии промышленных ядов при однократном воздействии. М., Медицина, 1977.
  5. Кузнецов В.П., Зуева В.С., Митренко О.А. и др. Антистафилококковая активность в препаратах интерферона. Антибиот. химиотерап. 1982, 7: 50—53.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2009 Volkova L.V., Kazyanin A.V., Tyureva T.A., Pestereva S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies